Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05434598 · ClinicalTrials.gov registry record · NA

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

A NA study of Myelodysplastic Syndromes and Whole Genome Sequencing, sponsored by Washington University School of Medicine.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05434598 is a NA study of Myelodysplastic Syndromes and Whole Genome Sequencing that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 60 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05434598, a NA study of Myelodysplastic Syndromes and Whole Genome Sequencing, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).

Interventions

  • DEVICE ChromoSeq

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-07-27
Est. Completion 2027-08-31
Phase NA

What the Registry Record Tells You About NCT05434598

The ClinicalTrials.gov registry entry for NCT05434598 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (79% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which ChromoSeq is the first listed.

NCT05434598 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05434598 about?

NCT05434598 is a clinical study titled "Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS". This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pati...

What is the current status of trial NCT05434598?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2022-07-27. Estimated completion is 2027-08-31.

What conditions does trial NCT05434598 study?

This clinical trial studies the following conditions: Myelodysplastic Syndromes, Whole Genome Sequencing.

What interventions are being tested in trial NCT05434598?

The interventions under investigation include: ChromoSeq (DEVICE).

Who is sponsoring clinical trial NCT05434598?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05434598 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.